{"id":"W2018929154","doi":"10.1200/jco.2007.12.1939","title":"Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":549,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Cyclophosphamide; Vascular endothelial growth factor; Regimen; Adverse effect; Ovarian cancer; Clinical endpoint; Oncology; Chemotherapy; Gastroenterology; Phases of clinical research; Cancer; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008533396,0.0002713726,0.003002232,0.0001740348,0.0000835547,0.000008573033,0.00023701,0.0005230026,0.0001118123],"category_scores_gemma":[0.003828328,0.0001730941,0.0007325527,0.0002353605,0.0008753283,0.00009150847,0.0002281943,0.001231901,5.798186e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003006287,"about_ca_system_score_gemma":0.00290459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002245922,"about_ca_topic_score_gemma":0.0005416175,"domain_scores_codex":[0.9921169,0.000712449,0.005915262,0.0004273246,0.0004551094,0.0003729317],"domain_scores_gemma":[0.9917852,0.002820833,0.004226531,0.0003515732,0.0002732395,0.0005426269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5124848,0.0433751,0.04882451,0.0000395832,0.0007225221,0.0001826118,0.0001412791,0.00000161404,0.00001162692,0.00008232317,0.0003375409,0.3937964],"study_design_scores_gemma":[0.7095241,0.175616,0.1015427,0.000304578,0.001201189,0.00004290776,0.00007159534,0.00005120429,0.0001381778,0.0001554576,0.01121905,0.0001330941],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984698,0.00151521,0.00002001298,0.007650081,0.004261062,0.001637379,0.0000937994,0.000004272688,0.0001202117],"genre_scores_gemma":[0.9926426,0.004770748,0.0007760521,0.0003474159,0.001392479,0.00002536072,0.000004882676,0.00002077386,0.00001965832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3936633,"threshold_uncertainty_score":0.7058572,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08053328566653827,"score_gpt":0.4726185715195743,"score_spread":0.392085285853036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}